Galectin-3 promotes chronic activation of k-ras and differentiation block in malignant thyroid carcinomas

Molecular Cancer Therapeutics

Volumn 9, Issue 8, 2010, Pages 2208-2219

  Levy, Ran ^a   Grafi Cohen, Meital ^b   Kraiem, Zaki ^c   Kloog, Yoel ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

FARNESYLTHIOSALICYLIC ACID; GALECTIN 3; GUANOSINE TRIPHOSPHATE; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P21; SALIRASIB; THYROID TRANSCRIPTION FACTOR 1; UNCLASSIFIED DRUG;

ANAPLASTIC CARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; THYROID CARCINOMA; TUMOR DIFFERENTIATION; TUMOR GROWTH;

ANIMALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL MEMBRANE; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FARNESOL; GALECTIN 3; GENE EXPRESSION REGULATION, NEOPLASTIC; GUANOSINE TRIPHOSPHATE; HUMANS; MICE; NUCLEAR PROTEINS; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SALICYLIC ACIDS; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TRANSCRIPTION FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77955477378     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0262     Document Type: Article

References (50)

1. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006;6:292-306.
2. Sherman SI. Thyroid carcinoma. Lancet 2003;361:501-11.
3. Hunt JL, Tometsko M, LiVolsi VA, et al. Molecular evidence of anaplastic transformation in coexisting well-differentiated and anaplastic carcinomas of the thyroid. Am J Surg Pathol 2003;27:1559-64.
4. Sipos JA, Mazzaferri EL. The therapeutic management of differentiated thyroid cancer. Expert Opin Pharmacother 2008;9:2627-37.
5. Kebebew E, Greenspan FS, Clark OH, et al. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 2005;103:1330-5.
6. Ahuja S, Ernst H. Chemotherapy of thyroid carcinoma. J Endocrinol Invest 1987;10:303-10.
7. Ros P, Rossi DL, Acebron A, et al. Thyroid-specific gene expression in the multi-step process of thyroid carcinogenesis. Biochimie 1999;81:389-96.
8. Liu FT, Patterson RJ, Wang JL. Intracellular functions of galectins. Biochim Biophys Acta 2002;1572:263-73.
9. Elad-Sfadia G, Haklai R, Balan E, et al. Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity. J Biol Chem 2004;279:34922-30. (Pubitemid 39318128)
10. Shalom-Feuerstein R, Makovski V, Levy R, et al. Galectin-3 regulates RasGRP4-mediated activation of N-Ras and H-Ras. Biochim Biophys Acta 2008;1783:985-93.
11. Shalom-Feuerstein R, Plowman SJ, Rotblat B, et al. K-ras nanoclustering is subverted by overexpression of the scaffold protein galectin-3. Cancer Res 2008;68:6608-16.
12. Boriack-Sjodin PA, Margarit SM, Bar-Sagi D, et al. The structural basis of the activation of Ras by Sos. Nature 1998;394:337-43.
13. Boguski MS, McCormick F. Proteins regulating Ras and its relatives. Nature 1993;366:643-54.
14. Crul M, de Klerk G, Beijnen JH, Schellens JH. Ras biochemistry and farnesyl transferase inhibitors: a literature survey. Anticancer Drugs 2001;12:163-84. (Pubitemid 32269912)
15. Berrozpe G, Schaeffer J, Peinado MA, et al. Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. Int J Cancer 1994;58:185-91.
16. Kolibaba KS, Druker BJ. Protein tyrosine kinases and cancer. Biochim Biophys Acta 1997;1333:F217-48.
17. Elad-Sfadia G, Haklai R, Ballan E, et al. Galectin-1 augments Ras activation and diverts Ras signals to Raf-1 at the expense of phosphoinositide 3-kinase. J Biol Chem 2002;277:37169-75.
18. Santoro M, Papotti M, Chiappetta G, et al. RET activation and clinicopathologic features in poorly differentiated thyroid tumors. J Clin Endocrinol Metab 2002;87:370-9.
19. Soares P, Trovisco V, Rocha AS, et al. BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Arch 2004;444:572-6.
20. Inohara H, Honjo Y, Yoshii T, et al. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer 1999;85:2475-84.
21. Saggiorato E, Aversa S, Deandreis D, et al. Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas. J Endocrinol Invest 2004;27:311-7.
22. Kraiem Z, Sadeh O, Yosef M. Iodide uptake and organification, triiodothyronine secretion, cyclic AMP accumulation and cell proliferation in an optimized system of human thyroid follicles cultured in collagen gel suspended in serum-free medium. J Endocrinol 1991;131:499-506.
23. Kraiem Z, Sadeh O, Yosef M, et al. Mutual antagonistic interactions between the thyrotropin (adenosine 3′,5′-monophosphate) and protein kinase C/epidermal growth factor (tyrosine kinase) pathways in cell proliferation and differentiation of cultured human thyroid follicles. Endocrinology 1995;136:585-90.
24. Liu D, Liu Z, Jiang D, et al. Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations. J Clin Endocrinol Metab 2007;92:4686-95. (Pubitemid 350223445)
25. Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003;88:4393-7.
26. Shalom-Feuerstein R, Cooks T, Raz A, et al. Galectin-3 regulates a molecular switch from N-Ras to K-Ras usage in human breast carcinoma cells. Cancer Res 2005;65:7292-300.
27. Marom M, Haklai R, Ben Baruch G, et al. Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid. J Biol Chem 1995;270:22263-70.
28. Blum R, Elkon R, Yaari S, et al. Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S- farnesylthiosalicylic acid). Cancer Res 2007;67:3320-8.
29. Estour B, Van Herle AJ, Juillard GJ, et al. Characterization of a human follicular thyroid carcinoma cell line (UCLA RO 82 W-1). Virchows Arch B Cell Pathol Incl Mol Pathol 1989;57:167-74.
30. Ouyang B, Knauf JA, Smith EP, et al. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res 2006;12:1785-93.
31. Liu D, Hu S, Hou P, et al. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin Cancer Res 2007;13:1341-9.
32. Carta C, Moretti S, Passeri L, et al. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)). Clin Endocrinol (Oxf) 2006;64:105-9.
33. Halaschek-Wiener J, Wacheck V, Kloog Y, et al. Ras inhibition leads to transcriptional activation of p53 and down-regulation of Mdm2: two mechanisms that cooperatively increase p53 function in colon cancer cells. Cell Signal 2004;16:1319-27. (Pubitemid 39165460)
34. Halaschek-Wiener J, Wacheck V, Schlagbauer Wadl H, Wolff K, Kloog Y, Jansen B. A novel Ras antagonist regulates both oncogenic Ras and the tumor suppressor p53 in colon cancer cells. Mol Med 2000;6:693-704.
35. Missero C, Pirro MT, Di Lauro R. Multiple ras downstream pathways mediate functional repression of the homeobox gene product TTF-1. Mol Cell Biol 2000;20:2783-93.
36. Akagi T, Luong QT, Gui D, et al. Induction of sodium iodide symporter gene and molecular characterisation of HNF3 β/FoxA2, TTF-1 and C/EBP β in thyroid carcinoma cells. British Journal of Cancer 2008;99:781-8.
37. De Vita G, Bauer L, da Costa VM, et al. Dose-dependent inhibition of thyroid differentiation by RAS oncogenes. Mol Endocrinol 2005;19:76-89.
38. Paz A, Haklai R, Elad-Sfadia G, et al. Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene 2001;20:7486-93. (Pubitemid 33086908)
39. Elad G, Paz A, Haklai R, et al. Targeting of K-Ras 4B by S-trans, trans-farnesyl thiosalicylic acid. Biochim Biophys Acta 1999;1452:228-42.
40. Weisz B, Giehl K, Gana-Weisz M, et al. A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice. Oncogene 1999;18:2579-88.
41. Gana-Weisz M, Halaschek-Wiener J, Jansen B, et al. The Ras inhibitor S-trans, trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance. Clin Cancer Res 2002;8:555-65.
42. Blum R, Jacob-Hirsch J, Amariglio N, et al. Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1α, causing glycolysis shutdown and cell death. Cancer Res 2005;65:999-1006. (Pubitemid 40216462)
43. Zundelevich A, Elad-Sfadia G, Haklai R, et al. Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid). Mol Cancer Ther 2007;6:1765-73.
44. Huang HS, Nagane M, Klingbeil CK, et al. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 1997;272:2927-35.
45. Smith JJ, Derynck R, Korc M. Production of transforming growth factor α in human pancreatic cancer cells: evidence for a superagonist autocrine cycle. Proc Natl Acad Sci U S A 1987;84:7567-70.
46. Fabbro D, Di Loreto C, Beltrami CA, et al. Expression of thyroid-specific transcription factors TTF-1 and PAX-8 in human thyroid neoplasms. Cancer Res 1994;54:4744-9. (Pubitemid 24276506)
47. Cobellis G, Missero C, Di Lauro R. Concomitant activation of MEK-1 and Rac-1 increases the proliferative potential of thyroid epithelial cells, without affecting their differentiation. Oncogene 1998;17:2047-57.
48. Francis-Lang H, Zannini M, De Felice M, et al. Multiple mechanisms of interference between transformation and differentiation in thyroid cells. Mol Cell Biol 1992;12:5793-800.
49. Fusco A, Berlingieri MT, Di Fiore PP, et al. One- and two-step transformations of rat thyroid epithelial cells by retroviral oncogenes. Mol Cell Biol 1987;7:3365-70.
50. Kupperman E, Wofford D, Wen W, et al. Ras inhibits thyroglobulin expression but not cyclic adenosine monophosphate-mediated signaling in Wistar rat thyrocytes. Endocrinology 1996;137:96-104.